Peptide Compounds Compared: Retatrutide, GLOW, and SEMTEX
Three research compounds. One protocol. Here is how Retatrutide anchors the stack and where GLOW and SEMTEX extend it.
The Three Compounds at a Glance
How Retatrutide Compares to Prior Research Generations
Each generation of receptor agonist research was more effective than the last. The progression is linear and the data is clear.
| Generation | Receptors Targeted | Mechanism | Research Outcome | What Retatrutide Adds |
|---|---|---|---|---|
| Single Receptor (Gen 1) | GLP-1 only | Appetite reduction via satiety signaling, glucose handling | Meaningful — established the pathway. Limited by single mechanism. | Retatrutide adds two additional receptor pathways and direct energy expenditure effects. |
| Dual Receptor (Gen 2) | GLP-1 + GIP | Appetite + lipid metabolism + insulin dual-pathway | Strong — improved body composition vs Gen 1. Better fat-to-lean ratios. | Retatrutide adds glucagon receptor activation, introducing thermogenic energy expenditure effects not present in dual agonists. |
| Triple Receptor (Retatrutide) | GLP-1 + GIP + Glucagon | Appetite + lipid metabolism + energy expenditure, all simultaneously | Up to 24% body weight reduction in Phase 2 — highest published figure for any non-surgical compound. | Current frontier of receptor agonist research. |
Retatrutide, GLOW, and SEMTEX are available through Werner Science. View the full catalog for compound specifications and current availability.
View Research Compounds →Why the Glucagon Receptor Is the Key Differentiator
Researchers familiar with the GLP-1 space often ask why adding the glucagon receptor matters so much — especially given glucagon's reputation as a blood sugar-raising hormone. The distinction is context.
In a metabolic research context, glucagon receptor activation does something specific: it increases hepatic fat oxidation and raises resting energy expenditure. The body starts burning more at baseline. When combined with the intake-reducing effects of GLP-1 activation and the lipid metabolism improvements of GIP activation, the result is a compound that works on all three sides of the energy equation simultaneously.
This is why the Phase 2 data looks the way it does. It is not one mechanism working harder — it is three complementary mechanisms working together. Retatrutide's 24% body weight reduction figure represents what that combination produces in a controlled research setting.
GLOW vs SEMTEX: Choosing Your Stack
For researchers who have established a Retatrutide protocol and are ready to extend it, GLOW and SEMTEX serve different purposes.
GLOW is the natural first complement. It addresses aspects of metabolic and body composition research that Retatrutide alone does not fully cover, and the two compounds have been studied together with consistent results. For most researchers, the Retatrutide + GLOW stack is the starting point for extended protocol work.
SEMTEX moves into more intensive territory. Researchers pursuing maximum protocol depth — those who have already documented baseline results with Retatrutide and GLOW — find SEMTEX adds a meaningful additional layer. The full three-compound stack represents the most comprehensive research framework currently available through Werner Science.
Ready to Explore the Research?
Retatrutide, GLOW, and SEMTEX are available through Werner Science. View the full peptide catalog for compound specifications, purity documentation, and current availability.
Shop Werner Science →Use code SAVE10 at checkout for 10% off.